ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
New Indication Approval for Ribociclib: A Game Changer for CDK4/6 Inhibitors
October 18, 2024Recently, the FDA officially approved Novartis's ribociclib, in combination with aromatase inhibitors (AI), for the adjuvant treatment of hormone receptor-positive (HR+)/ human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC) -
ASCO: Survival Up With Ribociclib in Advanced Breast Cancer
June 05, 2019Survival Up With Ribociclib in Advanced Breast Cancer. -
Ribociclib could be used to treat glioblastoma
November 21, 2018Ribociclib, a drug approved to treat breast cancer, could be used to treat one of the deadliest forms of cancer – glioblastoma… -
Novartis receives EU approval for ribociclib
August 25, 2017Novartis announced that the European Commission approved ribociclib in combination with an aromatase inhibitor for treatment of postmenopausal women with metastatic breast cancer
Pharma Sources Insight January 2025
